ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $433,178 | -17.2% | 195,125 | 0.0% | 0.05% | -18.2% |
| Q1 2024 | $522,935 | -10.4% | 195,125 | 0.0% | 0.07% | -17.5% |
| Q4 2023 | $583,424 | +205.1% | 195,125 | 0.0% | 0.08% | +175.9% |
| Q3 2023 | $191,223 | -29.5% | 195,125 | 0.0% | 0.03% | -25.6% |
| Q2 2023 | $271,224 | -12.6% | 195,125 | 0.0% | 0.04% | -18.8% |
| Q1 2023 | $310,249 | +391.8% | 195,125 | +1827.2% | 0.05% | +380.0% |
| Q4 2022 | $63,079 | -7.2% | 10,125 | 0.0% | 0.01% | -16.7% |
| Q3 2022 | $68,000 | +4.6% | 10,125 | 0.0% | 0.01% | +9.1% |
| Q2 2022 | $65,000 | +38.3% | 10,125 | 0.0% | 0.01% | +83.3% |
| Q1 2022 | $47,000 | -7.8% | 10,125 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $51,000 | -58.2% | 10,125 | 0.0% | 0.01% | -64.7% |
| Q3 2021 | $122,000 | -43.0% | 10,125 | 0.0% | 0.02% | -39.3% |
| Q2 2021 | $214,000 | -24.6% | 10,125 | 0.0% | 0.03% | -30.0% |
| Q1 2021 | $284,000 | +8.0% | 10,125 | 0.0% | 0.04% | -2.4% |
| Q4 2020 | $263,000 | -30.1% | 10,125 | 0.0% | 0.04% | -39.7% |
| Q3 2020 | $376,000 | -27.6% | 10,125 | 0.0% | 0.07% | -30.6% |
| Q2 2020 | $519,000 | +62.2% | 10,125 | 0.0% | 0.10% | +34.2% |
| Q1 2020 | $320,000 | -46.9% | 10,125 | 0.0% | 0.07% | -28.4% |
| Q4 2019 | $603,000 | +62.1% | 10,125 | 0.0% | 0.10% | +50.0% |
| Q3 2019 | $372,000 | -21.0% | 10,125 | 0.0% | 0.07% | -19.0% |
| Q2 2019 | $471,000 | +16.0% | 10,125 | 0.0% | 0.08% | +13.5% |
| Q1 2019 | $406,000 | -12.9% | 10,125 | 0.0% | 0.07% | -23.7% |
| Q4 2018 | $466,000 | -5.7% | 10,125 | -9.0% | 0.10% | +15.5% |
| Q3 2018 | $494,000 | -16.6% | 11,125 | -26.4% | 0.08% | -20.8% |
| Q2 2018 | $592,000 | -26.5% | 15,125 | +36.0% | 0.11% | -25.9% |
| Q1 2018 | $805,000 | -6.8% | 11,125 | -15.2% | 0.14% | -4.0% |
| Q4 2017 | $864,000 | +31.3% | 13,125 | 0.0% | 0.15% | +25.2% |
| Q3 2017 | $658,000 | – | 13,125 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $33,967,000 | 11.67% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $20,644,000 | 0.58% |
| Bellevue Group AG | 4,519,164 | $54,455,000 | 0.55% |
| Rhenman & Partners Asset Management AB | 622,267 | $7,498,000 | 0.53% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 47,534 | $573,000 | 0.21% |
| WASATCH ADVISORS LP | 3,274,360 | $39,456,000 | 0.16% |
| EMC Capital Management | 27,566 | $246,000 | 0.14% |
| PDT Partners, LLC | 120,828 | $1,456,000 | 0.10% |
| Virtus ETF Advisers LLC | 17,773 | $214,000 | 0.09% |
| Pinz Capital Management, LP | 15,300 | $184,000 | 0.08% |